Jaundice and hepatocellular damage associated with nevirapine therapy

American Journal of Gastroenterology

Volumn 96, Issue 5, 2001, Pages 1571-1574

  Prakash, Manish ^a   Poreddy, Vijayrama ^a   Tiyyagura, Lakshma ^a   Bonacini, Maurizio ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER CELL DAMAGE; LIVER FUNCTION TEST; LIVER TOXICITY; MALAISE; MALE; METABOLIC ACIDOSIS; PRIORITY JOURNAL; RASH;

EID: 0035016534     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02342-5     Document Type: Article

References (17)

1. Carr A., Vella S., DeJohn M.D., et al. A controlled trial of Nevirapine plus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS. 10:1996;635-641.
2. Havlir D., Cheeseman S.H., McLaughlin M., et al. High-dose nevirapine. Safety, pharmacokinetics and antiviral effect in patients with HIV infection. J Infect Dis. 171:1995;537-545.
3. D'Aquila R.T., Hughes M.D., Johnson V.A., et al. Nevirapine, zidovudine, and didanosine compared with zidovudine, and didanosine in patients with HIV-1 infection. Randomized, double blind, placebo-controlled trial. Ann Intern Med. 124:1996;1019-1030.
4. Cattelan A.M., Erne E., Salatino A., et al. Severe hepatic failure related to Nevirapine treatment. Clin Infect Dis. 29:1999;455-456.
5. Langlet P., Guillaume M.P., Devriendt J., et al. Fatal liver failure associated with nevirapine in a pregnant HIV patient The first reported case . Gastroenterology. 2000;A6623. (abstract).
6. Ho T.T.Y., Wong K.H., Chan K.C.W., Lee S.S. High incidence of nevirapine-associated rash in HIV-infected Chinese. AIDS. 12:1998;2082-2083.
7. Leitze Z., Nadeem A., Choudhary A., et al. Nevirapine-induced hepatitis treated with corticosteroids? AIDS. 12:1998;1115-1117.
8. Maria V.A.J., Victorino R.M.M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 26:1997;664-669.
9. Palella F., Delaney K., Moorman A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 448:1998;854-860.
10. Sulkowski M., Thomas D.L., Chaisson R.E., Moore R.D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 284:2000;74-80.
11. Physicians Desk Reference. 54th ed. Montvale, NJ: Medical Economics, 2000.
12. Bonacini M. Hepatobiliary complications in human immunodeficiency virus infection. Am J Med. 92:1992;404-411.
13. Vento S., Garofano T., Renzini C., et al. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS. 12:1998;116-117.
14. Rustschmann O.T., Negro F., Hirschel A., et al. Impact of treatment with human immunodeficiency virus protease inhibitors on hepatitis C viremia in patients' coinfected HIV. J Infect Dis. 177:1998;784-785.
15. Herzenberg L.A., De Rosa S.C., Dubs J.G., et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci USA. 94:1997;1967-1972.
16. Choi J., Liu R.M., Kundu R.K., et al. Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice. J Biol Chem. 275:2000;4694-4698.
17. Smith S.R., Boyd E.L., Kirking D.M. Nonprescription and alternative medication use by individuals with HIV disease. Ann Pharmacother. 44:1999;294-400.